Compare · CAH vs MDT
CAH vs MDT
Side-by-side comparison of Cardinal Health Inc. (CAH) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. CAH focuses on Other Pharmaceuticals, while MDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
- MDT is the larger of the two at $103.96B, about 2.3x CAH ($45.39B).
- Over the past year, CAH is up 32.4% and MDT is down 3.1% - CAH leads by 35.5 points.
- MDT has been more active in the news (22 items in the past 4 weeks vs 6 for CAH).
- Both have 25 recent analyst ratings on file.
- Company
- Cardinal Health Inc.
- Medtronic plc.
- Price
- $192.88-4.85%
- $80.99+2.05%
- Market cap
- $45.39B
- $103.96B
- 1M return
- -8.75%
- -6.52%
- 1Y return
- +32.45%
- -3.06%
- Industry
- Other Pharmaceuticals
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 6
- 22
- Recent ratings
- 25
- 25
Cardinal Health Inc.
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest CAH
- SEC Form 10-Q filed by Cardinal Health Inc.
- Cardinal Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook
- William Blair initiated coverage on Cardinal Health
- SEC Form 4 filed by Hall Patricia Hemingway
- Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings
- Cardinal Health expands Actinium-225 production capacity to support growing demand for novel cancer therapies
- Amendment: SEC Form SCHEDULE 13G/A filed by Cardinal Health Inc.
- Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2026 on April 30
- Cardinal Health Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
Latest MDT
- FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
- Chief Accounting Officer Blomquist Denise L. was granted 1,508 units of Ordinary Shares and covered exercise/tax liability with 318 units of Ordinary Shares, increasing direct ownership by 10% to 13,262 units (SEC Form 4)
- Director Nabel Elizabeth G was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 11% to 19,584 units (SEC Form 4)
- Director Powell Kendall J was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 4% to 51,380 units (SEC Form 4)
- Director Lofton Kevin E was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 23% to 10,140 units (SEC Form 4)
- Director Jellison William R was granted 1,444 units of Ordinary Shares, increasing direct ownership by 29% to 6,444 units (SEC Form 4)
- Director Lee Joon Sup was granted 1,803 units of Ordinary Shares (SEC Form 4)
- Director Lewis Gregory P was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 49% to 5,754 units (SEC Form 4)
- Director Hogan Randall J was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 4% to 48,998 units (SEC Form 4)
- Director Groetelaars John P was granted 1,444 units of Ordinary Shares (SEC Form 4)